Home > Healthcare > Pharmaceuticals > Finished Drug Form > Blood and Blood Components Market
Blood and Blood Components Market size accounted for USD 12.1 billion in 2021 and is estimated to grow with 3.4% CAGR between 2022 and 2028. Increasing number of people suffering from cancer coupled with various bleeding disorders will boost the business landscape over the estimation timeframe.
Blood and blood components are generally used in treatments including haematological diseases, cancer, etc. coupled with providing support during advanced surgical and medical procedures. According to the World Health Organization (WHO), more than 200 million major surgeries are performed per year globally. Additionally, there has been increasing trend towards application of blood and blood components such as platelet rich plasma (PRP) in various aesthetic procedures. This has significantly escalated the demand for blood and blood components including platelet and plasma that is set to benefit the market.
Report Attribute | Details |
---|---|
Base Year: | 2021 |
Blood and Blood Components Market Size in 2021: | USD 12,146.1 Million |
Forecast Period: | 2022 to 2028 |
Forecast Period 2022 to 2028 CAGR: | 3.4% |
2028 Value Projection: | USD 15,294.4 Million |
Historical Data for: | 2017 to 2021 |
No. of Pages: | 150 |
Tables, Charts & Figures: | 250 |
Segments covered: | Product, Application, End-use and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Plasma therapies has also witnessed substantial growth in major developing countries such as India and China to combat effect of COVID-19 in severe cases. Patients suffering from kidney failure or gastrointestinal bleeding experience chronic anaemia require transfusion of red blood cells (RBCs’). As per the Centres for Disease Control and Prevention (CDC) data, around 900,000 patients visit emergency department for anaemia every year globally. Thus, the widespread application of blood components in various fields of healthcare industry will drive the blood and blood components market growth significantly over the upcoming period.
Blood is life-sustaining fluid that circulates throughout the body providing nourishment, hormones, antibodies, electrolytes, and vitamins to body tissues. Blood components are components that are derived from whole blood and transfused to required patients using apheresis technique. These components are used in supporting advanced surgical and medical procedures along with application in haematological, cancer, cardiovascular, transplantation and aesthetic procedures. Thus, blood and blood components usage is gaining widespread popularity across varied regions.
The number of blood donors as well as donations has declined significantly in recent years especially during COVID-19 situation all over the globe. The American Red Cross has witnessed around 10% reduction in number of overall donors since the beginning of COVID-19 situation. Problems such as staffing limitations and blood drive cancellations have been faced by such organizations.
Moreover, the governments at country-level announced functioning of only emergency healthcare departments during the COVID-19 situation thus, affecting the aesthetic procedure industry. Blood is a product that cannot be stockpiled or manufactured, it can only be acquired through blood donations. Several blood organizations such as the European Blood Alliance and Australian Red Cross have started initiating blood awareness programs and donation camps to encourage people to donate blood. Blood and blood components that are majorly transfused can also be only acquired from blood hence, it is necessary for people to donate blood for proper management and function globally.
The decline in blood availability has elevated the number of people turning to black market in China to acquire supply of essential blood and blood components. Hence, the overall decline in blood donation will limit the market expansion to certain extent over the coming years.
The outbreak of COVID-19 pandemic had significantly impacted the blood and blood components market. The blood industry witnessed a significant drop in 2020-2021 owing to decline in blood transfusion procedures as a result of reduction in blood donation by people globally. This largely affected several blood transfusion operations.
Furthermore, the market players operating in the business revealed that overall transfusion numbers went down during the pandemic and eventually recovered due to the rise demand for blood components especially in case of cancer patients, anaemic patients and aesthetic procedures. A slow-moving growth was observed in blood and blood components business as several countries began with organizing blood donation campaigns in order to encourage people to donate blood.
Majority of cancer patients require transfusion of blood and blood components i.e., red blood cells as they also suffer from chronic anaemia condition. Cancer, particularly of digestive system leads to internal bleeding, thereby requiring blood component transfusion. Blood cells are produced in bone marrow however, in case of leukaemia or cancers that affect bone marrow function result in low blood count.
According to the American Cancer Society, there are over 60,000 new cases of leukaemia in the U.S. in 2022. Condition namely, anaemia is caused due to prolonged medical condition that negatively impacts the production and normal functioning of red blood cells.
Additionally, surgeries to treat certain type of cancer might also lead to blood loss, thereby lowering the blood cell count. Majority of chemotherapy drugs, radiation to treat large portion of bones also affect bone marrow, thereby lowering the overall blood cell counts that is set to prove beneficial for the blood and blood components market statistics.
By product, the market is segmented into whole blood and blood components. The blood components segment is further bifurcated into red blood cells, platelets, plasma, and white blood cells. Blood components segment accounted for over USD 11.6 billion market revenue in 2021. Blood components are essential during various surgeries and blood loss situations.
Moreover, certain conditions such as leukaemia or prolonged cancer treatment disrupts the production of blood components in bone marrow. Thus, requiring external supply of these components. Furthermore, aesthetic procedures including the Platelet Rich Plasma (PRP) therapy has gained immense popularity over the recent years.
Increasing number of people paying close attention towards their physical appearance and enhancement will further propel the platelet and plasma market over the forecast timeline. Also, the rise in orthopaedic diseases and sports injuries is set to escalate the demand for PRP therapy. Plasma contains proteins such as antibodies that help in fighting infection. It is also administered in bleeding patients to allow appropriate clotting of blood.
The blood and blood components market based on application is distinguished into anaemia, trauma & surgery, cancer treatment, bleeding disorders and others. The bleeding disorders segment is projected to surpass USD 3.5 billion by 2028. Patients suffering from Lymphoma, leukaemia, myelodysplastic syndrome, Idiopathic thrombocytopenic purpura, von Willebrand disease, etc. require external supply of these essential components as they are unable to produce naturally.
Majority of treatments also include surgeries that result in loss of blood also requires blood supply externally. Anaemia in many forms including iron-deficiency anaemia, pernicious anaemia, aplastic anaemia etc. affects the bone marrow thus, depleting the supply of red blood cells. In such cases, patients are provided with external supply of RBCs’. In cases such as Malaria that is highly prevalent in Africa, the parasite transmitted into patient’s bloodstream ruptures the red blood cells causing fever and organ damage.
In such cases, the red blood cells are required to be administered to the patients. Thus, the increasing incidence of bleeding disorders will increase the demand for blood and blood components.
By end-use, the blood and blood components market is divided into hospitals, ambulatory surgical centres and others. The ambulatory surgical centres segment accounted for around 23% business share in 2021. Cost-effectiveness offered by ambulatory surgical centres coupled with surgeons’ choice of treatment are factors propelling the end-use segment expansion.
Surgeries that do not require stay are majorly conducted in ambulatory centres across the developed countries. There has been significant rise for ambulatory centres in developing countries creating new growth opportunities for the market players. Increase in number of surgeries and patients suffering from chronic illnesses will further augment the market statistics.
Europe blood and blood components market accounted for USD 4 billion in 2021. Supportive regulatory system in the region stimulates the growth of market. It also encourages people to donate blood by organizing various blood donation camps and blood donation awareness programs. The European Blood Alliance also functions to bring new innovative changes in its current management model in order to further enhance region’s blood management.
For instance, the organization worked with European commission to develop Europe wide open access platform containing details about convalescent plasma therapy administered to people suffering from coronavirus infection in the region. The Big data test infrastructure developed in Europe has benefitted overall citizen experience, as well as elevated the government’s operating efficiency in provision of required blood components on time wherever required.
The open access platform also allows researchers in gaining better understanding of disease traits and in development of new treatment. Hence, the increase in number of awareness and initiative programs will augment the regional blood and blood components market growth.
Major market players operating in the blood and blood components industry include:
Market participants are focusing towards increasing number of blood donations in order to fulfil the demand globally. They are adopting various inorganic strategies such as partnership to encourage people for the same.
For instance, the European Plasma Alliance organizes various donation camps to support plasma donation in the region to fulfil increasing plasma demand in the region. Moreover, these organizations are also working towards lowering fear of transfusion transmitted infection (TTI) among public by adopting proper blood handling and storage guidelines issues by respective health authorities. Such initiatives undertaken by these market players will positively impact the industry growth.
Some of the recent industry developments:
The blood and blood components market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2022 to 2028, for the following segments:
Click here to Buy Section of this Report
By Product
By Application
By End-use
The above information is provided for the following regions and countries:
By Region